AI assistant
STRIDES PHARMA SCIENCE LIMITED Capital/Financing Update 2020
62616_rns_2020-04-20_21c0eea4-63ef-4c2e-9a3d-d4a5a2a67359.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
April 20, 2020
BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001
Exchange Plaza, Bandra-Kurla Complex Bandra (E) Mumbai - 400 051
The National Stock Exchange of India Limited
Scrip code: 532531
Scrip code: STAR
Dear Madam/ Sir,
Subject: Press Release
Please find attached Press Release issued by the Company titled:
"Strides receives USFDA approval for Flucytosine Capsules"
Thanking you,
Yours faithfully, For Strides Pharma Science Limited
Manjula Ramamurthy Company Secretary
Encl. As above
Strides Pharma Science Limited
(Formerly Strides Shasun Limited) CIN: L24230MH1990PLC057062 Corp Off: Strides House, Bilekahalli, Bannerghatta Road, Bangalore - 560 076, India Tel: +91 80 6784 0000 Fax: +91 80 6784 0700 Regd Off: 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942 [email protected]; www.strides.com
April 20, 2020
Strides receives USFDA approval for Flucytosine Capsules
Product approval from flagship facility in Bangalore To be marketed by Strides Pharma Inc. in the US market
Bangalore, April 20, 2020 ‐ Strides Pharma Science Limited (Strides) today announced that its step‐down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Flucytosine Capsules USP, 250 mg and 500 mg from the United States Food & Drug Administration (USFDA). The product is a generic version of Ancobon® Capsules, 250 mg and 500 mg, of Bausch Health US, LLC.
According to IQVIA MAT data, the US market for Flucytosine Capsules USP, 250 mg and 500 mg is approximately US$ 45 Mn. The product will be manufactured at the company's flagship facility at Bangalore and will be marketed by Strides Pharma Inc. in the US market.
The company has 123 cumulative ANDA filings with USFDA of which 86 ANDAs have been approved and 37 are pending approval.
About Flucytosine Capsules
Flucytosine Capsule is indicated only in the treatment of serious infections caused by susceptible strains of Candida (septicemia, endocarditis and urinary system infections) and/or Cryptococcus (meningitis and pulmonary infections).
About Strides
Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India. The Company mainly operates in the regulated markets and has an "in Africa for Africa" strategy along with an institutional business to service donor‐funded markets. The Company's global manufacturing sites are located in India‐ Bangalore (two locations), Pondicherry, and Chennai, Singapore, Italy‐ Milan, Kenya‐ Nairobi and United States‐Florida. The Company focusses on "difficult to manufacture" productsthat are sold in over 100 countries. Additional information is available at the Company's website at www.strides.com
For further information, please contact:
| Strides | PRConsultancy |
|---|---|
| BadreeKomandur | FortunaPR |
| ExecutiveDirector ‐ Finance | KSrinivasReddy:+919000527213 |
| +918067840747 | [email protected] |
| InvestorRelations | KPriya:+919535425418 |
|---|---|
| Kannan.N:+919845054745 | [email protected] |
| VikeshKumar:+918067840827 | |
| SandeepBaid:+918067840791 | |
| Email:[email protected] | |
| StridesPharmaScienceLimited | |
| (FormerlyStridesShasunLimited) | |
| CIN:L24230MH1990PLC057062 | |
| Regd.Office:201,'Devavrata',Sector ‐ 17, | |
| Vashi,NaviMumbai ‐ 400703 | |
| Corp.Office:StridesHouse,Bannerghatta | |
| Road,Bangalore–560076 |